Protein kinase C epsilon-dependent extracellular signal-regulated kinase 5 phosphorylation and nuclear translocation involved in cardiomyocyte hypertrophy with angiotensin II stimulation

Journal of Cellular Biochemistry

Volumn 109, Issue 4, 2010, Pages 653-662

  Zhao, Zhuo ^a,b   Wang, Wei ^c   Geng, Jing ^a   Wang, Liqi ^b   Su, Guohai ^b   Zhang, Yun ^a   Ge, Zhiming ^a   Kang, Weiqiang ^a  

^a SHANDONG UNIVERSITY   (China)

^b JINAN CENTRAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^c SHANDONG PROVINCIAL CHEST HOSPITAL   (China)

Author keywords

Angiotensin II; Cardiomyocyte; ERK5; Hypertrophy; PKC

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; 2 [1 (3 DIMETHYLAMINOPROPYL) 5 METHOXY 1H INDOL 3 YL] 3 (1H INDOL 3 YL)MALEIMIDE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN II; LEUCINE; MITOGEN ACTIVATED PROTEIN KINASE 7; PROTEIN KINASE C EPSILON; PROTEIN KINASE C INHIBITOR; SMALL INTERFERING RNA; TRITIUM; VALSARTAN;

ANIMAL CELL; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG TARGETING; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HEART HYPERTROPHY; HEART MUSCLE CELL; HYPERTENSION; NEWBORN; NONHUMAN; NUCLEOCYTOPLASMIC TRANSPORT; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ACTIVE TRANSPORT, CELL NUCLEUS; ANGIOTENSIN II; ANIMALS; CELL ENLARGEMENT; HYPERTROPHY; MITOGEN-ACTIVATED PROTEIN KINASE 7; MYOCYTES, CARDIAC; MYOGENIC REGULATORY FACTORS; PHOSPHORYLATION; PROTEIN KINASE C-EPSILON; RATS;

RATTUS;

EID: 77749340985     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.22441     Document Type: Article

References (55)

1. Akaike M, Che W, Marmarosh NL, Ohta S, Osawa M, Ding B, Berk BC, Yan C, Abe J. 2004. The hinge-helix 1 region of peroxisome proliferator-activated receptor gamma 1(PPARgamma 1) mediates interaction with extracellular signal-regulated kinase 5 and PPARgamma 1 transcriptional activation: Involvement in flow-induced PPARgamma activation in endothelial cells. Mol Cell Biol 24:8691-8704.
2. Behr TM, Nerurkar SS, Nelson AH, Coatney RW, Woods TN, Sulpizio A, Chandra S, Brooks DP, Kumar S, Lee JC, Ohlstein EH, Angermann CE, Adams JL, Sisko J, Sackner-Bernstein JD, Willette RN. 2001. Hypertensive endorgan damage and premature mortality are p38 mitogen-activated protein kinase-dependent in a rat model of cardiac hypertrophy and dysfunction. Circulation 11:1292-1298.
3. Bowling N, Walsh RA, Song G, Estridge T, Sandusky GE, Fouts RL, Mintze K, Pickard T, Roden R, Bristow MR, Sabbah HN, Mizrahi JL, Gromo G, King GL, Vlahos CJ. 1999. Increased protein kinase C activity and expression of Ca2+-sensitive isoforms in the failing human heart. Circulation 99:384-391.
4. Braz JC, Gregory K, Pathak A, Zhao W, Sahin B, Klevitsky R, Kimball TF, Lorenz JN, Nairn AC, Liggett SB, Bodi I, Wang S, Schwartz A, Lakatta EG, DePaoli-Roach AA, Robbins J, Hewett TE, Bibb JA, Westfall MV, Kranias EG, Molkentin JD. 2004. PKC-alpha regulates cardiac contractility and propensity toward heart failure. Nat Med 10:248-254.
5. Brede M, Roell W, Ritter O, Wiesmann F, Jahns R, Haase A, Fleischmann BK, Hein L. 2003. Cardiac hypertrophy is associated with decreased eNOS expression in angiotensin AT2 receptor-deficient mice. Hypertension 42:1177-1182.
6. Bueno OF, De Windt LJ, Lim HW, Tymitz KM, Witt SA, Kimball TR, Molkentin JD. 2001. The dual-specificity phosphatase MKP-1 limits the cardiac hypertrophic response in vitro and in vivo. Circ Res 88:88-96.
7. Buschbeck M, Ullrich A. 2005. The unique C-terminal tail of mitogenactivated protein kinase ERK5 regulates its activation and nuclear shuttling. J Biol Chem 280:2659-2667.
8. Cai J, Yi FF, Bian ZY, Shen DF, Yang L, Yan L, Tang QZ, Yang XC, Li H. 2009. Crocetin protects against cardiac hypertrophy by blocking MEK-ERK1/2 signalling pathway. J Cell Mol Med 13:909-925.
9. Chen L, Hahn H, Wu G, Chen CH, Liron T, Schechtman D, Cavallaro G, Banci L, Guo Y, Bolli R, Dorn GW II, Mochly-Rosen D. 2001. Opposing cardioprotective actions and parallel hypertrophic effects of delta PKC and epsilon PKC. Proc Natl Acad Sci USA 98(20): 11114-11119.
10. Coulombe P, Meloche S. 2007. Atypical mitogen-activated protein kinases: Structure, regulation and functions. Biochim Biophys Acta 1773:1376-1387.
11. D'Angelo DD, Sakata Y, Lorenz JN, Boivin GP, Walsh RA, Liggett SB, Dorn GW II. 1997. Transgenic Galphaq overexpression induces cardiac contractile failure in mice. Proc Natl Acad Sci USA 94:8121-8126.
12. Dempsey EC, Newton AC, Mochly-Rosen D, Fields AP, Reyland ME, Insel PA, Messing RO. 2000. Protein kinase C isozymes and the regulation of diverse cell responses. Am J Physiol Lung Cell Mol Physiol 279:L429-L438.
13. Dorn GW II, Force T. 2005. Protein kinase cascades in the regulation of cardiac hypertrophy. J Clin Invest 115:527-537.
14. Dorn GW, Mochly-Rosen D. 2002. Intracellular transport mechanisms of signal transducers. Annu Rev Physiol 64:407-429.
15. Elbashir SM, Harborth J, Weber K, Tuschl T. 2002. Analysis of gene function in somatic mammalian cells using small interfering RNAs. Methods 26:199-213.
16. Fabris B, Candido R, Bortoletto M, Zentilin L, Sandri M, Fior F, Toffoli B, Stebel M, Bardelli M, Belgrado D, Giacca M, Carretta R. 2007. Dose- and timedependent apoptotic effects by angiotensin II infusion on left ventricular cardiomyocytes. J Hypertens 25:1481-1490.
17. Finn SG, Dickens M, Fuller SJ. 2001. c-Jun N-terminal kinase/interacting protein 1 inhibits gene expression in response to hypertrophic agonists in neonatal rat ventricular myocytes. Biochem J 358:489-495.
18. García-Hoz C, Herranz M, Teresa Díaz-Meco M, Moscat J, Ribas C, Mayor F, Jr. 2007. PKC delta mediated GalphaQ stimulation of the ERK5 pathway plays a key role in cardiac hypertrophy. J Mol Cell Cardiol 42:S37-S54.
19. Griendling KK, Lassegue B, Alexander RW. 1996. Angiotensin receptors and their therapeutic implications. Annu Rev Pharmacol Toxicol 36:281-306.
20. Gu X, Bishop SP. 1994. Increased protein kinase C and isozyme redistribution in pressure-overload cardiac hypertrophy in the rat. Circ Res 75:926-931.
21. Joerg H, Jeffery DM. 2006. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol 7:589-600.
22. Kondoh K, Terasawa K, Morimoto H, Nishida E. 2006. Regulation of c-Fos and Fra-1 by the MEK5-ERK5 pathway. Mol Cell Biol 26:1679-1690.
23. Luo JD, Xie F, Zhang WW, Ma XD, Guan JX, Chen X. 2001. Simvastatin inhibits noradrenaline-induced hypertrophy of cultured neonatal rat cardiomyocytes. Br J Pharmacol 132:159-164.
24. Mehta PK, Griendling KK. 2007. Angiotensin II cell signaling: Physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol 292:C82-C97.
25. Minamino T, Komuro I. 2007. Vascular cell senescence: Contribution to atherosclerosis. Circ Res 100(1): 15-26.
26. Mollmann H, Schmidt-Schweda S, Nef H, Mollmann S, Burtsin JV, Klose S, Elsässer A, Holubarsch CJ. 2007. Contractile effects of angiotensin and endothelin in failing and non-failing human hearts. Int J Cardiol 114:34-40.
27. Murray NR, Thompson LJ, Fields AP. 1997. The role of protein kinase C in cellular proliferation and cell cycle control. In: Parker PJ, Dekker L, editors. Molecular biology intelligence unit. Austin, Texas, USA: Landes. pp 97-120.
28. Nicol RL, Frey N, Olson EN. 2000. From the sarcomere to the nucleus: Role of genetics and signaling in structural heart disease. Annu Rev Genomics Hum Genet 1:179-223.
29. Nishimoto S, Nishida E. 2006. MAPK signalling: ERK5 versus ERK1/2. EMBO Rep 7:782-786.
30. Ozgen N, Obreztchikova M, Guo J, Elouardighi H, Dorn GW II, Wilson BA, Steinberg SF. 2008. Protein kinase D links Gq-coupled receptors to cAMP response element-binding protein (CREB)-Ser133 phosphorylation in the heart. J Biol Chem 283:17009-17019.
31. Pellieux C, Sauthier T, Aubert JF, Brunner HR, Pedrazzini T. 2000. Angiotensin II-induced cardiac hypertrophy is associated with different mitogenactivated protein kinase activation in normotensive and hypertensive mice. J Hypertens 18:1307-1317.
32. Poizat C, Sartorelli V, Chung G, Kloner RA, Kedes L. 2000. Proteasomemediated degradation of the coactivator p300 impairs cardiac transcription. Mol Cell Biol 20:8643-8654.
33. Raviv Z, Kalie E, Seger R. 2004. MEK5 and ERK5 are localized in the nuclei of resting as well as stimulated cells, while MEKK2 translocates from the cytosol to the nucleus upon stimulation. J Cell Sci 117:1773-1784.
34. Regan CP, Li W, Boucher DM, Spatz S, Su MS, Kuida K. 2002. Erk5 null mice display multiple extraembryonic vascular and embryonic cardiovascular defects. Proc Natl Acad Sci USA 99:9248-9253.
35. Sabri A, Steinberg SF. 2003. Protein kinase C isoform-selective signals that lead to cardiac hypertrophy and the progression of heart failure. Mol Cell Biochem 251:97-101.
36. Schlüter KD, Wenzel S. 2008. Angiotensin II: A hormone involved in and contributing to pro-hypertrophic cardiac networks and target of antihypertrophic cross-talks. Pharmacol Ther 119:311-325.
37. Sharma G, Goalstone ML. 2007. Regulation of ERK5 by insulin and angiotensin-II in vascular smooth muscle cells. Biochem Biophys Res Commun 354:1078-1083.
38. Shin SY, Yang JM, Choo SM, Kwon KS, Cho KH. 2008. System-level investigation into the regulatory mechanism of the calcineurin/NFAT signaling pathway. Cell Signal 20:1117-1124.
39. Steinberg SF. 2008. Structural basis of protein kinase C isoform function. Physiol Rev 88:1341-1378.
40. Takahashi N, Saito Y, Kuwahara K, Harada M, Tanimoto K, Nakagawa Y, Kawakami R, Nakanishi M, Yasuno S, Usami S, Yoshimura A, Nakao K. 2005.
41. Hypertrophic responses to cardiotrophin-1 are not mediated by STAT3, but via a MEK5-ERK5 pathway in cultured cardiomyocytes. J Mol Cell Cardiol 38:185-192.
42. Takeishi Y, Ping P, Bolli R, Kirkpatrick DL, Hoit BD, Walsh RA. 2000. Transgenic overexpression of constitutively active protein kinase C epsilon causes concentric cardiac hypertrophy. Circ Res 86(12): 1218-1223.
43. Touyz RM, Berry C. 2002. Recent advances in angiotensin II signaling. Braz J Med Biol Res 35:1001-1015.
44. Vega RB, Harrison BC, Meadows E, Roberts CR, Papst PJ, Olson EN, McKinsey TA. 2004. Protein kinases C and D mediate agonist-dependent cardiac hypertrophy through nuclear export of histone deacetylase 5. Mol Cell Biol 24:8374-8385.
45. Wang Y. 2007. Mitogen-activated protein kinases in heart development and diseases. Circulation 116:1413-1423.
46. Wang X, Tournier C. 2006. Regulation of cellular functions by the ERK5 signalling pathway. Cell Signal 18:753-760.
47. Wang Y, Su B, Sah VP, Brown JH, Han J, Chien KR. 1998. Cardiac hypertrophy induced by mitogen-activated protein kinase kinase 7, a specific activator for c-Jun NH2-terminal kinase in ventricular muscle cells. J Biol Chem 273:5423-5426.
48. Wang X, Merritt AJ, Seyfried J, Guo C, Papadakis ES, Finegan KG, Kayahara M, Dixon J, Boot- Handford RP, Cartwright EJ, Mayer U, Tournier C. 2005. Targeted deletion of mek5 causes early embryonic death and defects in the extracellular signal-regulated kinase 5/myocyte enhancer factor 2 cell survival pathway. Mol Cell Biol 25:336-345.
49. Yan C, Luo H, Lee JD, Abe J, Berk BC. 2001. Activation of a C-terminal transcriptional activation domain of ERK5 by autophosphorylation. J Biol Chem 276:10870-10878.
50. Yan L, Carr J, Ashby PR, Murry-Tait V, Thompson C, Arthur JS. 2003. Knockout of ERK5 causes multiple defects in placental and embryonic development. BMC Dev Biol 3:11.
51. Yan Y, Rubinchik S, Watson PM, Kelley JR, Fraser MM, Wood AL, Dong JY, Gillanders WE, Boylan AM, Watson DK, Cole DJ. 2005. Yan Establishing a murine pancreatic cancer CaSm model: up-regulation of CaSm is required for the transformed phenotype of murine pancreatic adenocarcinoma. Mol Ther 11:363-372.
52. Yutao X, Geru W, Xiaojun B, Tao G, Aquin M. 2006. Mechanical stretchinduced hypertrophy of neonatal rat ventricular myocytes is mediated by β(1)-integrin-microtubule signalling pathways. Eur J Heart Fail 8: 16-22.
53. Zhan Y, Brown C, Maynard E, Anshelevich A, Ni W, Ho IC, Oettgen P. 2005. Ets-1 is a critical regulator of Ang II-mediated vascular inflammation and remodeling. J Clin Invest 115:2508-2516.
54. Zhao Z, Geng J, Ge Z, Wang W, Zhang Y, Kang W. 2009. Activation of ERK5 in angiotensin II-induced hypertrophy of human aortic smooth muscle cells. Mol Cell Biochem 322:171-178.
55. Zou XJ, Yang L, Yao SL. 2008. Propofol depresses angiotensin II-induced cardiomyocyte hypertrophy in vitro. Exp Biol Med (Maywood) 233:200-208